Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb and its Japanese partner Otsuka Pharmaceutical have introduced two new formulations of Abilify, the companies' drug for the treatment of schizophrenia and bipolar disorder.
Subscribe to our email newsletter
The drug will now be available to patients and physicians in a 2 mg tablet strength and as a nonrefrigerated oral solution. Previously the drug was only available in higher dose tablet formulations.
According to the company, the 2 mg tablet equips physicians with an additional dosage strength to help them titrate patients to an effective dose. Whilst the nonrefrigerated oral solution formulation allows greater convenience for adults who are unable to swallow or have difficulty swallowing tablets.
Abilify is specifically indicated for the treatment of schizophrenia, acute manic and mixed episodes associated with bipolar I disorder, and for maintaining efficacy in adults who have had a recent manic or mixed bipolar I episode, but have been stabilized and maintained for at least six weeks. The drug is the first and only available dopamine partial agonist.